ITP
Iron Triangle Partners Portfolio holdings
AUM
$875M
1-Year Est. Return
49.85%
This Fund
S&P 500
1 Year Est. Return
+49.85%
AUM
$875M
AUM Growth
+$171M
(+24%)
Holding
41
Top Buys
| 1 | +$50.3M | |
| 2 | +$41.3M | |
| 3 | +$38.7M | |
| 4 |
Bruker
BRKR
|
+$33.6M |
| 5 |
Vertex Pharmaceuticals
VRTX
|
+$33.2M |
Top Sells
| 1 | +$57.2M | |
| 2 | +$46.4M | |
| 3 | +$43.2M | |
| 4 |
CVS Health
CVS
|
+$28.8M |
| 5 |
Glaukos
GKOS
|
+$28M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Dianthus Therapeutics
DNTH
$2.39B
| $9.51M | 1.09% |
+230,730
|
|
||
27
Mineralys Therapeutics
MLYS
$2.26B
| $9.33M | 1.07% |
+257,085
|
|
||
28
AbbVie
ABBV
$414B
| – | – |
-200,326
|
|
||
29
Adaptive Biotechnologies
ADPT
$2.47B
| – | – |
-1,820,915
|
|
||
30
argenx
ARGX
$46.3B
| – | – |
-9,900
|
|
||
31
West Pharmaceutical
WST
$18.1B
| – | – |
-70,000
|
|
||
32
Cardinal Health
CAH
$53.3B
| – | – |
-138,011
|
|
||
33
DexCom
DXCM
$28.1B
| – | – |
-850,000
|
|
||
34
Exact Sciences
EXAS
$19.7B
| – | – |
-500,000
|
|
||
35
Amicus Therapeutics
FOLD
$4.5B
| – | – |
-1,971,260
|
|
||
36
Guardant Health
GH
$12.2B
| – | – |
-400,000
|
|
||
|
37
Glaukos
GKOS
$6.84B
| – | – |
-342,804
|
|
||
38
Madrigal Pharmaceuticals
MDGL
$9.67B
| – | – |
-58,378
|
|
||
39
Medtronic
MDT
$124B
| – | – |
-453,347
|
|
||
40
Neurocrine Biosciences
NBIX
$13.2B
| – | – |
-131,390
|
|
||
41
Tenet Healthcare
THC
$21.1B
| – | – |
-137,448
|
|